Research progress on mesenchymal stem cell products and their exosomes in the treatment of inflammatory bowel disease
10.11665/j.issn.1000-5048.2023113001
- VernacularTitle:间充质干细胞产品及其外泌体在炎症性肠病治疗中的研究进展
- Author:
Jingwen YANG
1
;
Qian CHEN
;
Yunlong SHAN
;
Jiali LIU
;
Ning WEI
;
Jing WANG
;
Guangji WANG
;
Fang ZHOU
Author Information
1. 中国药科大学药物代谢动力学重点实验室
- Publication Type:Journal Article
- Keywords:
inflammatory bowel disease / mesenchymal stem cells / exosomes / engineering
- From:
Journal of China Pharmaceutical University
2024;55(1):103-114
- CountryChina
- Language:Chinese
-
Abstract:
Abstract: Inflammatory bowel disease (IBD), whose pathogenesis remains elusive, is a group of autoimmune diseases characterized by chronic, progressive, and lifelong inflammation of the digestive tract. The pathogenesis of IBD remains elusive. Although a number of drugs have been developed to treat IBD, their effects are merely anti-inflammatory. In addition, current treatments for IBD are easily susceptible to resistance in clinical practice. Mesenchymal stem cells (MSCs) have been reported to have the ability to migrate to the site of inflammation, with potent immunoregulatory effects, and to rebalance the immune microenvironment and restore the integrity of the epithelial barrier with significant value of application, particularly for patients who are refractory to classic medicines. In this paper, we reviewed the clinical applications, mechanisms and engineerable properties of MSC products and their exosomes to provide some reference for the use of MSCs and their exosomes in the treatment of IBD.
